反応式
Cl.[Cl:2][C:3]1[CH:22]=[CH:21][C:6]([O:7][C:8]2[CH:9]=[C:10]([CH:18]=[CH:19][CH:20]=2)[CH2:11][N:12]2[CH2:17][CH2:16][NH:15][CH2:14][CH2:13]2)=[CH:5][CH:4]=1.C(N(C(C)C)CC)(C)C.C1([O:38][C:39](=O)[NH:40][C:41]2[N:45]3[N:46]=[CH:47][CH:48]=[CH:49][C:44]3=[N:43][CH:42]=2)C=CC=CC=1>CS(C)=O.CCOC(C)=O>[N:43]1[CH:42]=[C:41]([NH:40][C:39]([N:15]2[CH2:16][CH2:17][N:12]([CH2:11][C:10]3[CH:18]=[CH:19][CH:20]=[C:8]([O:7][C:6]4[CH:21]=[CH:22][C:3]([Cl:2])=[CH:4][CH:5]=4)[CH:9]=3)[CH2:13][CH2:14]2)=[O:38])[N:45]2[C:44]=1[CH:49]=[CH:48][CH:47]=[N:46]2参加物
反応物 3
生成物 1
試薬・触媒・溶媒 2
反応条件
- 温度
- 50 °C
実験手順
To a solution of 1-[3-(4-chloro-phenoxy)-benzyl]-piperazine hydrochloride (62.3 mg, 0.166 mmol) and diisopropylethylamine (53.7 mg, 0.416 mmol) in DMSO (2.0 mL) was added imidazo[1,2-b]pyridazin-3-yl-carbamic acid phenyl ester (42.1 mg, 0.166 mmol). The reaction mixture was stirred at 50° C. for 16 h, then diluted with EtOAc (40 mL) and washed with saturated aqueous NaHCO3 (40 mL). The organic layer was dried (MgSO4) and concentrated. The crude residue was purified (FCC, 2 N NH3 in MeOH/DCM) to give 4-[3-(4-chloro-phenoxy)-benzyl]-piperazine-1-carboxylic acid imidazo[1,2-b]pyridazin-3-ylamide (67.1 mg, 87%). MS (ESI+): calcd for C24H23ClN6O2 m/z 462.16, found 463.5 (M+H)+. 1H NMR (d6-DMSO): 8.74 (s, 1H), 8.50 (dd, J=4.4, 1.3, 1H), 8.05 (dd, J=9.1, 1.3, 1H), 7.64 (s, 1H), 7.44 (d, J=9.0, 2H), 7.38 (t, J=7.8, 1H), 7.19-7.12 (m, 2H), 7.04 (d, J=9.0, 2H), 7.01 (br s, 1H), 6.95-6.92 (m, 1H), 3.53 (s, 2H), 3.50-3.45 (m, 4H), 2.43-2.37 (m, 4H).
後処理
- washwashed with saturated aqueous NaHCO3 (40 mL)
- dry with materialThe organic layer was dried (MgSO4)
- concentrationconcentrated
- customThe crude residue was purified (FCC, 2 N NH3 in MeOH/DCM)
出典と根拠
- ORDレコード
- ord-e040b9e6303641d8b2290f8e35202707
- 出典データセット
- uspto-grants-2014_11
- 特許番号
- US08877769B2
関連ノート
読み込み中…